NCT05923502View on ClinicalTrials.gov

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Follicular LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRichter SyndromeMarginal Zone LymphomaPeripheral T Cell LymphomaDiffuse Large B Cell Lymphoma
Interventions
DRUG

Duvelisib

This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT05923502 - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | Biotech Hunter | Biotech Hunter